Comparing adjuvanted H28 and Modified Vaccinia Virus Ankara expressing H28 in a mouse and a non-human primate tuberculosis model

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Billeskov, Rolf ^a,b   Christensen, Jan P ^b   Aagaard, Claus ^a   Andersen, Peter ^a   Dietrich, Jes ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANTED RECOMBINANT H28 PROTEIN VACCINE; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MODIFIED VACCINIA VIRUS ANKARA H28 VACCINE; PEPTIDE VACCINE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOGENICITY; MACACA FASCICULARIS; MEMORY CELL; MOUSE; MOUSE MODEL; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SURVIVAL RATE; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CHIMERA; COMPARATIVE STUDY; GENE EXPRESSION; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS;

MUS; PRIMATES; VACCINIA VIRUS ANKARA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHIMERA; FEMALE; GENE EXPRESSION; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA VIRUS;

EID: 84905103996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072185     Document Type: Article

References (57)

1. Anon (2011) Global tuberculosis control: WHO report 2011. Geneva, Switzerland: World Health Organization.
2. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, et al. (2002) Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185: 401-404.
3. Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
4. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, et al. (1995) The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96: 29-35.
5. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature [see comments]. JAMA 271: 698-702.
6. Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB (1999) Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189: 1973-1980.
7. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR (1992) Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. ProcNatlAcadSciUSA 89: 12013-12017.
8. Chen CY, Huang D, Wang RC, Shen L, Zeng G, et al. (2009) A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 5: e1000392.
9. Leveton C, Barnass S, Champion B, Lucas S, De-Souza B, et al. (1989) T-cell-mediated protection of mice against virulent Mycobacterium tuberculosis. Infect. Immun. 57: 390-395.
10. Saunders BM, Cheers C (1995) Inflammatory response following intranasal infection with Mycobacterium avium complex: role of T-cell subsets and gamma interferon. Infect. Immun. 63: 2282-2287.
11. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178: 2243-2247.
12. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178: 2249-2254.
13. Dorman SE, Holland SM (2000) Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 11: 321-333.
14. Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, et al. (2010) Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 5: e9611.
15. Beresford B, Sadoff JC (2010) Update on research and development pipeline: tuberculosis vaccines. Clin. Infect. Dis. 50 Suppl 3: S178-183.
16. Doherty TM, Dietrich J, Billeskov R (2007) Tuberculosis subunit vaccines: from basic science to clinical testing. Expert. Opin. Biol. Ther. 7: 1539-1549.
17. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, et al. (2009) Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182: 8047-8055.
18. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
19. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181: 4955-4964.
20. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, et al. (2011) Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187: 2222-2232.
21. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, et al. (2010) Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 40: 2211-2220.
22. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO (2009) Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39: 723-729.
23. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, et al. (2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M. Tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4: e5264.
24. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, et al. (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77: 3364-3373.
25. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacteri-um tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171: 1602-1609.
26. Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, et al. (2006) Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet. Infect. Dis. 6: 522-528.
27. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10: 1240-1244.
28. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, et al. (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198: 544-552.
29. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-8.
30. Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, et al. (2009) Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. Tuberculosis antigen 85A against murine tuberculosis. Infect. Immun. 77: 622-631.
31. Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, et al. (2010) Establishment of an aerosol challenge model of tuberculosis in rhesus macaques, and an evaluation of endpoints for vaccine testing. Clin. Vaccine. Immunol. 8: 1170-82.
32. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, et al. (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28: 3571-3581.
33. Aagaard C, Dietrich J, Doherty M, Andersen P (2009) TB vaccines: current status and future perspectives. Immunol. Cell. Biol. 87: 279-286.
34. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, et al. (2005) Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174: 6332-6339.
35. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43: 717-731.
36. Aagaard C, Hoang T, Dietrich J, Cardona P-J, Izzo A, et al. (2011) A multistage tuberculosis vaccine that confers efficient protection pre-and post-exposure. Nature Medicine. 2: 189-94.
37. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, et al. (2012) The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 122: 303-314.
38. Suter M, Meisinger-Henschel C, Tzatzaris M, Hulsemann V, Lukassen S, et al. (2009) Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27: 7442-7450.
39. Dietrich J, Billeskov R, Doherty TM, Andersen P (2007) Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J. Immunol. 178: 3721-3730.
40. Billeskov R, Elvang TT, Andersen PL, Dietrich J (2012) The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7: e39909.
41. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J (2007) Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J. Immunol. 179: 3973-3981.
42. Roederer M, Nozzi JL, Nason MC (2011) SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
43. Bonferroni CE (1936) Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze 8: 29.
44. Capuano SV,. (2003) Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. Tuberculosis infection. Infect. Immun. 71: 5831-5844.
45. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, et al. (2011) Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29: 2100-2109.
46. Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, et al. (2009) CD4 and CD8 T cell responses to the M. Tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 4: e5139.
47. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258.
48. Obst R, van Santen HM, Mathis D, Benoist C (2005) Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J. Exp. Med. 201: 1555-1565.
49. Williams MA, Bevan MJ (2004) Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J. Immunol. 173: 6694-6702.
50. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrom T, Agger EM, et al. (2011) Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3beta-[N-(N', N'-Dimethyla-minoethane)carbomyl] cholesterol (DC-Chol), and 1, 2-Dioleoyl-3-trimethylam-monium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 8: 153-161.
51. Henao-Tamayo M, Obregon-Henao A, Ordway DJ, Shang S, Duncan CG, et al. (2012) A mouse model of tuberculosis reinfection. Tuberculosis (Edinb) 92: 211-217.
52. Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, et al. (2010) Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis. Rheum. 62: 340-350.
53. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, et al. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
54. Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, et al. (2009) Efficacy and safety of live attenuated persistent and rapidly cleared Mycobac-terium tuberculosis vaccine candidates in non-human primates. Vaccine 27: 4709-4717.
55. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, et al. (2009) Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl. Acad. Sci. U S A 106: 2301-2306.
56. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, et al. (2009) Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 27: 3267-3270.
57. Flynn JL (2006) Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 8: 1179-1188.